HIV/AIDS Clinical Trials

A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

Condition: HIV-1; HIV Infections

NCT ID: NCT00355524

A Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women

Condition: HIV; HIV Infections; Pregnancy

NCT ID: NCT00855335

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Condition: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus

NCT ID: NCT01448707

Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir

Condition: HIV Infections; AIDS Virus; Human Immunodeficiency Virus; Acquired Immunodeficiency Syndrome Virus

NCT ID: NCT00458302

Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT01516970

Phase 3b Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01440569

Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01565850

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

Condition: Human Immunodeficiency Virus; HIV

NCT ID: NCT01541085

Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT00993148

Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.

Condition: HIV-1 Infection; HIV Infections

NCT ID: NCT00849160

TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) Previously

Condition: HIV Infections

NCT ID: NCT00513513

An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients

Condition: Human Immunodeficiency Virus (HIV)

NCT ID: NCT01615601

TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains

Condition: HIV Infections

NCT ID: NCT00964327

Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)

Condition: HIV; HIV Infections

NCT ID: NCT00928187

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

Condition: Acquired Immunodeficiency Syndrome; HIV Infections

NCT ID: NCT01363011

The First Failure Study

Condition: HIV; HIV Infections

NCT ID: NCT01118871

Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136

Condition: HIV Infections

NCT ID: NCT00421551

Dual Therapy With Raltegravir and Darunavir/Ritonavir in HIV Infected Patients.

Condition: HIV Integrase, HIV Protease.

NCT ID: NCT01258374

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

Condition: HIV Infections

NCT ID: NCT00245739

Approved for marketing

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses

Condition: HIV Infections

NCT ID: NCT00460382

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

Condition: HIV Infection

NCT ID: NCT00081588

TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients

Condition: HIV Infections

NCT ID: NCT00071097

Study of Darunavir/r + Tenofovir/Emtricitabine vs. Darunavir/r + Raltegravir in HIV-infected Antiretroviral naïve Subjects

Condition: HIV Infections

NCT ID: NCT01066962

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

Condition: HIV Infections

NCT ID: NCT00115050

TMC114-TiDP29-C228 - A Safety Study to Evaluate the Antiviral Activity of Darunavir (DRV) in Combination With Ritonavir (Rtv) in HIV 1 Infected Children From 3 Years to Below 6 Years of Age

Condition: HIV Infections

NCT ID: NCT00919854

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

Condition: HIV Infections

NCT ID: NCT00525733

Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications

Condition: Opioid Dependency; HIV Infections

NCT ID: NCT00877591

TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients

Condition: HIV Infection

NCT ID: NCT00110877

A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients

Condition: Human Immunodeficiency Virus-Type 1

NCT ID: NCT01726348

Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)

Condition: HIV-1 Infections

NCT ID: NCT01033760

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Condition: HIV-1 Infection

NCT ID: NCT00915655

Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue

Condition: HIV/AIDS; HIV Infections

NCT ID: NCT00855088

DRV/r + RPV QD: Efficacy and Toxicity Reduction

Condition: HIV-positive Subjects With HIV-RNA <50 Copies/mL

NCT ID: NCT01792570

Part A: Drug Interaction Study of GS-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: Phase 2, Open-Label Study to Investigate Efficacy and Safety of GS-7977 for 12 Weeks in HIV/HCV Co-infected Patients.

Condition: Hepatitis C; HIV

NCT ID: NCT01565889

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Condition: HIV Infections

NCT ID: NCT00307502

A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).

Condition: HIV-1 Infection

NCT ID: NCT00534352

A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT01391013

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

Condition: HIV Infections

NCT ID: NCT01047995

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

Condition: HIV Infections; Infection

NCT ID: NCT00381303

Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection

Condition: HIV

NCT ID: NCT01343225

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Condition: HIV-1

NCT ID: NCT00823979

Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

Condition: HIV; HIV Infections

NCT ID: NCT01073761

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

Condition: HIV-1 Infections

NCT ID: NCT00830804

Completed(En español)

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Condition: Human Immunodeficiency Virus-1

NCT ID: NCT00827112

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With Ccr5 Tropic HIV 1

Condition: HIV-1

NCT ID: NCT01345630

A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)

Condition: Human Immunodeficiency Virus - Type 1

NCT ID: NCT00524368

Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment

Condition: HIV

NCT ID: NCT00757783

Metabolic Safety of Raltegravir Versus Darunavir in HIV Naive Patients

Condition: Cardiovascular Disease; HIV Infections

NCT ID: NCT01066065

TMC114-C211: Trial of an Investigational Protease Inhibitor TMC114 With Ritonavir ("TMC114/r") in HIV-1 Infected Patients Who Have Never Been Treated With Antiretroviral Medications.

Condition: HIV

NCT ID: NCT00258557

Characterization of Acute and Recent HIV-1 Infections in Zurich: a Long-Term Observational Study

Condition: HIV Infections

NCT ID: NCT00537966

DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects

Condition: HIV

NCT ID: NCT01423812

Non-interventional Study on Use of Darunavir With Ritonavir in Clinical Practice

Condition: HIV Infections

NCT ID: NCT01375881

TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

Condition: HIV

NCT ID: NCT00650832

Double Protease Inhibitor to Darunavir Switch Study

Condition: HIV Infections

NCT ID: NCT00531557

Darunavir Levels, Virological Efficacy, Proviral ADN and Resistances in Patients on Darunavir/Ritonavir Monotherapy

Condition: HIV-infection

NCT ID: NCT01606722

Tissue Drug Levels of HIV Medications

Condition: Human Immunodeficiency Virus

NCT ID: NCT01490346

Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01199731

Early Access to TMC114/r and Other AVT for Treatment-naive or Early Treatment Experienced in HIV-1 Patients

Condition: HIV-1

NCT ID: NCT01702090

Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

Condition: HIV-1 Adults Patients; AIDS; Triple Class Failure

NCT ID: NCT01013987

TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV

Condition: HIV-1 Infections

NCT ID: NCT01281813

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

Condition: HIV

NCT ID: NCT00765271

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Condition: HIV

NCT ID: NCT01605084

Withdrawn

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Condition: HIV

NCT ID: NCT00254046

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

Condition: HIV

NCT ID: NCT00255099

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Condition: HIV; Impaired Cognition

NCT ID: NCT01367236

Active, not recruiting(En español)

Comparative Study of Three NNRTI-Sparing HAART Regimens

Condition: HIV Infection

NCT ID: NCT00811954

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Condition: HIV Infections

NCT ID: NCT00260078

Completed(En español)

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

Condition: HIV-1 Infections

NCT ID: NCT01138605

TMC114-TiDP3-C182 - A Study to Compare the Oral Bioavailability of a 800 mg Prototype Tablet Formulation of Darunivar (DRV) to That of the 400 mg Commercial Tablet Formulation in the Presence of Low Dose Ritonavir, Under Fasted and Fed Conditions

Condition: HIV Infections

NCT ID: NCT01052883

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

Condition: HIV

NCT ID: NCT00460746

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Condition: Infection, Human Immunodeficiency Virus

NCT ID: NCT01449929

Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen

Condition: HIV-1 Infection

NCT ID: NCT01400412

Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study

Condition: HIV Infections

NCT ID: NCT00885495

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

Condition: HIV Infections; Hyperlipidemia

NCT ID: NCT00630734

Switch to Darunavir/r + Maraviroc QD in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)

Condition: HIV Infection

NCT ID: NCT01367210

Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients

Condition: HIV Infections

NCT ID: NCT00677300

Clinical Study to Evaluate the Efficacy and Safety of Lopinavir/Ritonavir Monotherapy Versus Darunavir/Ritonavir Monotherapies as Simplification Switching Strategies of PI/NNRTI-Triple Therapy Based-Regimens

Condition: HIV Infections

NCT ID: NCT00994344

Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir

Condition: HIV Infections

NCT ID: NCT01294761

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

Condition: HIV Infections

NCT ID: NCT00543101

Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r

Condition: HIV Infections

NCT ID: NCT00756730

MARCH Central Nervous System Substudy

Condition: HIV-1 Infection

NCT ID: NCT01637233

Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients

Condition: Hepatitis B; Human Immunodeficiency Virus; Hepatitis C, Chronic

NCT ID: NCT00782301

Withdrawn

Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors

Condition: HIV-1 Infection

NCT ID: NCT01480713

A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.

Condition: HIV

NCT ID: NCT01736761

Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification Strategy

Condition: HIV Infections

NCT ID: NCT00611039

Drug Interactions Between Echinacea Purpurea and Darunavir/Ritonavir

Condition: HIV Infections

NCT ID: NCT01046890

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

Condition: HIV Infections

NCT ID: NCT01374802

Active, not recruiting(En español)

Optimizing Treatment for Treatment-Experienced, HIV-infected People

Condition: HIV Infections

NCT ID: NCT00537394

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Condition: HIV Infections

NCT ID: NCT00517192

NNRTI/PI Toxicity Switch to Darunavir Study

Condition: HIV

NCT ID: NCT00765154

The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study

Condition: HIV

NCT ID: NCT01348763

Pharmacokinetic Effects of New Antiretroviral Drugs on Children, Adolescents and Young Adults

Condition: HIV Infections

NCT ID: NCT00977756

Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected Patients

Condition: HIV-1

NCT ID: NCT01274780

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Condition: HIV-1 Infection

NCT ID: NCT01641367

Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz

Condition: Hyperlipidemia; HIV

NCT ID: NCT01695954

Post-prandial Lipid Effects of Raltegravir (RAL) vs Ritonavir -Boosted Darunavir (DRV-r) in Anti-retroviral Therapy (ART)- Naive Adults or Adults Recommencing ART.

Condition: HIV; Cardiovascular Disease

NCT ID: NCT01258439

A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista

Condition: Acquired Immune Deficiency Syndrome

NCT ID: NCT01741831

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

Condition: HIV; Asthma

NCT ID: NCT00936793

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

Condition: HIV-1

NCT ID: NCT00838760

Drug Interaction Study of Darunavir/Ritonavir and Lopinavir/Ritonavir on GSK2248761 PK and CYP450 Probe Drugs

Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

NCT ID: NCT00920088

GSK1349572 Drug Interaction Study With Protease Inhibitors

Condition: Healthy Subjects; Infection, Human Immunodeficiency Virus

NCT ID: NCT00774735

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

Condition: HIV-1

NCT ID: NCT00359021

MARCH Renal Substudy

Condition: Proteinuria; HIV

NCT ID: NCT01637259

Active, not recruiting(En español)

Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters

Condition: HIV Infections; Treatment Naive

NCT ID: NCT00851799

Drug Interactions Between Silimarine and Darunavir/Ritonavir

Condition: HIV

NCT ID: NCT01346982

TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.

Condition: HIV; AIDS

NCT ID: NCT00744887

INROADS, Abbreviated Title: Intelence aNd PRezista Once A Day Study

Condition: HIV

NCT ID: NCT01199939

A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study

Condition: HIV

NCT ID: NCT01680536

VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.

Condition: Hepatitis C; Telaprevir; HIV

NCT ID: NCT00775125

Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629

Condition: HIV-I

NCT ID: NCT00854204

Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Condition: HIV; Hepatitis C; Liver Fibrosis

NCT ID: NCT01231685

Antiretroviral Therapy and Extreme Weight

Condition: HIV Infection

NCT ID: NCT01805427

Comparative Tolerability of Protease Inhibitors

Condition: HIV

NCT ID: NCT01450618

A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022

Condition: HIV-1

NCT ID: NCT01254656

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

Condition: HIV Infections

NCT ID: NCT01026727

Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

Condition: ADHD; HIV

NCT ID: NCT01232361

Drug Exposure Registry for GSK2248761, an Investigational NNRTI

Condition: Seizures; Infection, Human Immunodeficiency Virus

NCT ID: NCT01458132

Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Condition: HIV; HIV Infections

NCT ID: NCT00966329

Pilot Opened Trial in HIV-infected Patients Including an Investigational Marketed Product

Condition: HIV Infections

NCT ID: NCT00773708

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

Condition: This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy.

NCT ID: NCT01225406

Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut

Condition: HIV Infections

NCT ID: NCT00884793

Clinical Trial of CNS-targeted HAART (CIT2)

Condition: HIV Infections

NCT ID: NCT00624195

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

Condition: HIV-1

NCT ID: NCT00665847

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

Condition: HIV-1 Infection

NCT ID: NCT01252940

Immune Activation and Drug Absorption in HIV-Infected Patients

Condition: HIV Infection

NCT ID: NCT01845298

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Condition: HIV Infections

NCT ID: NCT00042289

Recruiting(En español)

TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Condition: Healthy

NCT ID: NCT01308658

A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions

Condition: Healthy Participants

NCT ID: NCT01619527